title: Multimodal treatment strategy for locally advanced breast cancer.
abstract: Between 1990 and 1995, 87 patients with locally advanced breast cancer were treated with initial chemotherapy consisting of 3-4 cycles of epirubicin and then with surgery, radiotherapy and chemotherapy. All patients with positive or unknown estrogen receptor status were administered tamoxifen. A complete response was observed in 9 patients and a partial response in 64. At a mean follow-up of 29.22 months, 25 patients had died of metastatic disease, and 48 patients are disease-free. 54% patients are alive at 5 years. Statistical analysis confirmed that neither age, menopausal status, size of the primary tumor nor histology seemed to influence the Disease Free and Overall Survival. Improved survival was observed in patients with negative lymph nodes and positive receptor status. The presence of a positive receptor status may be correlated with conserved integrity of hormone sensitivity and with a good response to the hormone therapy.
authors.affiliation: Divisione di Endocrinologica Oncologica, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy.
authors.forename: A
authors.initials: A
authors.lastname: De Matteis
authors.forename: M
authors.initials: M
authors.lastname: Montella
authors.forename: M
authors.initials: M
authors.lastname: Iannuzzo
authors.forename: M R
authors.initials: MR
authors.lastname: De Marco
authors.forename: G
authors.initials: G
authors.lastname: Landi
authors.forename: V
authors.initials: V
authors.lastname: Labonia
authors.forename: P
authors.initials: P
authors.lastname: Frezza
authors.forename: M
authors.initials: M
authors.lastname: Cerra
authors.forename: P
authors.initials: P
authors.lastname: Oliviero
authors.forename: G
authors.initials: G
authors.lastname: D'Aiuto
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D002277:Carcinoma / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015411:Mastectomy, Modified Radical; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D011960:Receptors, Estrogen / Q000032:analysis; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D013629:Tamoxifen; D015251:Epirubicin